Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Pipeline
  • Rejuvenate crowdfunds development of gene therapy for aging, chronic diseases
  • Pipeline

Rejuvenate crowdfunds development of gene therapy for aging, chronic diseases

BioSpace

George Church's Rejuvenate Bio is turning to social networks to help fund its work on one-time gene therapies targeting chronic diseases and root causes of aging.

Gene Therapy Platform

Read full story

pharminent April 27, 2026 (Last updated: April 27, 2026)

BioSpace

George Church’s Rejuvenate Bio is turning to social networks to help fund its work on one-time gene therapies targeting chronic diseases and root causes of aging.

Gene Therapy Platform

Read full story

Post navigation

Previous: J&J puts blockbuster blood thinner Xarelto on TrumpRx
Next: GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio

Related Stories

  • Pipeline

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

pharminent August 11, 2026
  • Pipeline

Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease

pharminent August 11, 2026
  • Pipeline

BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication

pharminent August 10, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.